Emre Altinmakas1,2,3, Octavia Bane1,2, Stefanie J Hectors1,2, Rayane Issa1, Guillermo Carbonell2,4, Ghadi Abboud1,2, Thomas D Schiano5, Swan Thung6, Aaron Fischman1, Matthew D Kelly7, Scott L Friedman8, Paul Kennedy1,2, Bachir Taouli9,10. 1. Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, New York, NY, 10029, USA. 2. BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Radiology, Koc University School of Medicine, Istanbul, Turkey. 4. Department of Radiology, Virgen de La Arrixaca University Clinical Hospital, University of Murcia, Murcia, Spain. 5. Icahn School of Medicine at Mount Sinai, Recanati/Miller Transplantation Institute, New York, NY, USA. 6. Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 7. Perspectum, Oxford, UK. 8. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 9. Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, New York, NY, 10029, USA. bachir.taouli@mountsinai.org. 10. BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. bachir.taouli@mountsinai.org.
Abstract
PURPOSE: In this preliminary study, our aim was to assess the utility of quantitative native-T1 (T1-pre), iron-corrected T1 (cT1) of the liver/spleen and T1 mapping of the liver obtained during hepatobiliary phase (T1-HBP) post-gadoxetate disodium, compared to spleen size/volume and APRI (aspartate aminotransferase-to-platelet ratio index) for noninvasive diagnosis of clinically significant portal hypertension [CSPH, defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg]. METHODS: Forty-nine patients (M/F: 27/22, mean age 53y) with chronic liver disease, HVPG measurement and MRI were included. Breath-held T1 and cT1 measurements were obtained using an inversion recovery Look-Locker sequence and a T2* corrected modified Look-Locker sequence, respectively. Liver T1-pre (n = 49), spleen T1 (obtained pre-contrast, n = 47), liver and spleen cT1 (both obtained pre-contrast, n = 30), liver T1-HBP (obtained 20 min post gadoxetate disodium injection, n = 36) and liver T1 uptake (ΔT1, n = 36) were measured. Spleen size/volume and APRI were also obtained. Spearman correlation coefficients were used to assess the correlation between each of liver/spleen T1/cT1 parameters, spleen size/volume and APRI with HVPG. ROC analysis was performed to determine the performance of measured parameters for diagnosis of CSPH. RESULTS: There were 12/49 (24%) patients with CSPH. Liver T1-pre (r = 0.287, p = 0.045), liver T1-HBP (r = 0.543, p = 0.001), liver ΔT1 (r = - 0.437, p = 0.008), spleen T1 (r = 0.311, p = 0.033) and APRI (r = 0.394, p = 0.005) were all significantly correlated with HVPG, while liver cT1, spleen cT1 and spleen size/volume were not. The highest AUCs for the diagnosis of CSPH were achieved with liver T1-HBP, liver ΔT1 and spleen T1: 0.881 (95%CI 0.76-1.0, p = 0.001), 0.852 (0.72-0.98, p = 0.002) and 0.781 (0.60-0.95, p = 0.004), respectively. CONCLUSION: Our preliminary results demonstrate the potential of liver T1 mapping obtained during HBP post gadoxetate disodium for the diagnosis of CSPH. These results require further validation.
PURPOSE: In this preliminary study, our aim was to assess the utility of quantitative native-T1 (T1-pre), iron-corrected T1 (cT1) of the liver/spleen and T1 mapping of the liver obtained during hepatobiliary phase (T1-HBP) post-gadoxetate disodium, compared to spleen size/volume and APRI (aspartate aminotransferase-to-platelet ratio index) for noninvasive diagnosis of clinically significant portal hypertension [CSPH, defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg]. METHODS: Forty-nine patients (M/F: 27/22, mean age 53y) with chronic liver disease, HVPG measurement and MRI were included. Breath-held T1 and cT1 measurements were obtained using an inversion recovery Look-Locker sequence and a T2* corrected modified Look-Locker sequence, respectively. Liver T1-pre (n = 49), spleen T1 (obtained pre-contrast, n = 47), liver and spleen cT1 (both obtained pre-contrast, n = 30), liver T1-HBP (obtained 20 min post gadoxetate disodium injection, n = 36) and liver T1 uptake (ΔT1, n = 36) were measured. Spleen size/volume and APRI were also obtained. Spearman correlation coefficients were used to assess the correlation between each of liver/spleen T1/cT1 parameters, spleen size/volume and APRI with HVPG. ROC analysis was performed to determine the performance of measured parameters for diagnosis of CSPH. RESULTS: There were 12/49 (24%) patients with CSPH. Liver T1-pre (r = 0.287, p = 0.045), liver T1-HBP (r = 0.543, p = 0.001), liver ΔT1 (r = - 0.437, p = 0.008), spleen T1 (r = 0.311, p = 0.033) and APRI (r = 0.394, p = 0.005) were all significantly correlated with HVPG, while liver cT1, spleen cT1 and spleen size/volume were not. The highest AUCs for the diagnosis of CSPH were achieved with liver T1-HBP, liver ΔT1 and spleen T1: 0.881 (95%CI 0.76-1.0, p = 0.001), 0.852 (0.72-0.98, p = 0.002) and 0.781 (0.60-0.95, p = 0.004), respectively. CONCLUSION: Our preliminary results demonstrate the potential of liver T1 mapping obtained during HBP post gadoxetate disodium for the diagnosis of CSPH. These results require further validation.
Authors: Siddharth Singh; Sudhakar K Venkatesh; Rohit Loomba; Zhen Wang; Claude Sirlin; Jun Chen; Meng Yin; Frank H Miller; Russell N Low; Tarek Hassanein; Edmund M Godfrey; Patrick Asbach; Mohammad Hassan Murad; David J Lomas; Jayant A Talwalkar; Richard L Ehman Journal: Eur Radiol Date: 2015-08-28 Impact factor: 5.315
Authors: Julian A Luetkens; Sabine Klein; Frank Träber; Frederic C Schmeel; Alois M Sprinkart; Daniel L R Kuetting; Wolfgang Block; Frank E Uschner; Robert Schierwagen; Kanishka Hittatiya; Glen Kristiansen; Juergen Gieseke; Hans H Schild; Jonel Trebicka; Guido M Kukuk Journal: Radiology Date: 2018-06-26 Impact factor: 11.105
Authors: Octavia Bane; Stefanie J Hectors; Mathilde Wagner; Lori L Arlinghaus; Madhava P Aryal; Yue Cao; Thomas L Chenevert; Fiona Fennessy; Wei Huang; Nola M Hylton; Jayashree Kalpathy-Cramer; Kathryn E Keenan; Dariya I Malyarenko; Robert V Mulkern; David C Newitt; Stephen E Russek; Karl F Stupic; Alina Tudorica; Lisa J Wilmes; Thomas E Yankeelov; Yi-Fei Yen; Michael A Boss; Bachir Taouli Journal: Magn Reson Med Date: 2017-09-14 Impact factor: 4.668
Authors: Naaventhan Palaniyappan; Eleanor Cox; Christopher Bradley; Robert Scott; Andrew Austin; Richard O'Neill; Greg Ramjas; Simon Travis; Hilary White; Rajeev Singh; Peter Thurley; Indra Neil Guha; Susan Francis; Guruprasad Padur Aithal Journal: J Hepatol Date: 2016-07-27 Impact factor: 25.083
Authors: Narine Mesropyan; Alexander Isaak; Anton Faron; Michael Praktiknjo; Christian Jansen; Daniel Kuetting; Carsten Meyer; Claus C Pieper; Alois M Sprinkart; Johannes Chang; Burkhard Maedler; Daniel Thomas; Patrick Kupczyk; Ulrike Attenberger; Julian A Luetkens Journal: Eur Radiol Date: 2020-08-04 Impact factor: 5.315